Formulation and pharmacology of long-acting rilpivirine

Current Opinion in HIV and AIDS

Volumn 10, Issue 4, 2015, Pages 233-238

  Williams, Peter E ^a   Crauwels, Herta M ^a   Basstanie, Esther D ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Cabotegravir; Long acting injectable antiretroviral; Nanosuspension; Rilpivirine

Indexed keywords

CABOTEGRAVIR; LONG ACTING DRUG; POLOXAMER; RILPIVIRINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG FORMULATION; DRUG SOLUBILITY; FIRST IN HUMAN STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SUSPENSION; VIRUS LOAD; CHEMISTRY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RILPIVIRINE;

EID: 84943155308     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000164     Document Type: Review

References (33)

1. Joint United Nations Programme on HIV and AIDS (UNAIDS). World AIDS Day 2014 Report. Fast-Track: ending the AIDS epidemic by 2030. Geneva, Switzerland. UNAIDS 2014. http://www.unaids.org/sites/default/files/med-ia-asset/JC2686-WAD2014report-en.pdf. [Accessed on 23 December 2014]
2. Whiteside YO, Cohen SM, Bradley H, et al. Progress along the continuum of HIV care among blacks with diagnosed HIV: United States 2010. Morbid Mortal Week Rep 2014; 5:63.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
4. Fauci AS, Marston HD, Ending AIDS. Is an HIV vaccine necessary? New Engl J Med 2014; 370:495-498.
5. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
6. Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
7. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethe-nyl]-2, 6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48:1901-1909.
8. Azijn H, Thirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleo-side reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54:718-727.
9. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278- A novel NNRTI-in treatment-näive HIV-1-infected subjects. AIDS 2006; 20:1721-1726.
10. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-näive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24:55-65.
11. Cohen CJ, Molina J-M, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 2013; 27:939-950.
12. Casado JL, Bañón S. Recent advances in rilpivirine: new data and promising treatment option. AIDS Rev 2014; 16:172-181.
13. McEvoy JP. Risks versus benefits of different types of long-acting antipsy-chotics. J Clin Psychiatry 2006; 67 (Suppl 5):15-18.
14. Dolgin E. Long-actingHIV drugs advanced to overcome adherence challenge. Nature Med 2014; 20:323-324.
15. INVEGA SUSTENNA (paliperidone palmitate) Extended-release Injectable Suspension, Label Information. Janssen Pharmaceuticals Inc. 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022264s013s014lbl.pdf [Accessed on 13 March 2015].
16. Baert L, van 't Klooster G, Dries W, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009; 72:502-508.
17. Kesteleyn B, Amssoms K, Schepens W, et al. Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. Bio Med Chem Lett 2013; 23:310-317.
18. Van 't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting inject-able antiretroviral formulation. Antimicrob Agents Chemother 2010; 54:2042-2050.
19. Van 't Klooster G, Verloes R, Baert L, et al. Long-acting TMC278, a parenteral-depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings, Abstract no. 134. 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA; 2008.
20. Verloes R, Van 't Klooster G, Baert L, et al. TMC278 long acting- A parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers, Abstract no. TUPE0042. XVIIth International AIDS Conference, Mexico City, Mexico; 2008.
21. Mende FS. Production of nanodispersions. Advances in Plastics Technology International Conference. Conference Papers 8th; Katowice, Poland; 2009. pp. 483-491.
22. Verloes R, Deleu S, Niemeijer N, et al. Safety, tolerability and pharmacoki-netics of rilpivirine following administration of a long-acting formulation in healthy volunteers. HIV Medicine 2015; DOI: 10.1111/hiv.12247.
23. Schafer JJ, Short WR. Rilpivirine, a novel nonnucleoside reverse transcriptase inhibitor for the management of HIV-1 infection; a systematic review. Antivir Ther 2012; 17:1495-1502.
24. Paton NI, Kityo S, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371: 234-247.
25. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24:223-230.
26. Spreen WS, Margolis DA, Pottage JC. Long acting antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8:565-571.
27. Margolis DA, Brinson CC, Eron JJ, et al. 744 and Rilpivirine As Two Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results. Abstract no. 91LB. 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA; 2014.
28. Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 2014; 67:487-492.
29. Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine 2013; 8:1807-1813.
30. High rate of willingness to consider injectable anti-HIV therapy as an option in this survey of attitudes among infected patients.
31. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725-735.
32. Jackson AG, Else LJ, Mesquita PM, et al. A Compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharm Ther 2014; 96:314-323.
33. nd Conference on Retroviruses and Opportunistic Infections; Seattle, WA; 2015.